Hanall Biopharma & Daewoong Pharmaceutical announce U.S. Phase II clinical trial of new dry eye therapy

Published: 2018-05-31 17:08:48

Updated: 2018-05-31 17:08:48

On the 29^th, Hanall Biopharma and Daewoong Pharmaceutical announced their U.S. Phase II clinical trial(a.k.a. Topline) result of the dry eye treatment biosimilar HL036 that they are jointly developing. The Phase II clinical trial was conducted at 2 ophthalmic clinical trial centers in Boston through a company called Ora, a U.S. ophthalmic CRO.

Doctor George Ousler, the senior researcher of the...

Fees

- Email service daily and homepage access.

$300 per month.
5 Email holders per each company.
Anual contract base.